Advertisement

The Use of Ricin a Chain-Containing Immunotoxins to Kill Neoplastic B Cells

  • Ellen S. Vitetta
  • Jonathan W. Uhr

Abstract

Paul Ehrlich first discussed the potential use of antibodies as carriers of pharmacologic agents. During the last 10 years there have been many attempts to apply this concept to the elimination of neoplastic and other target cells using antibodies coupled to toxic agents. A cell-binding antibody conjugated to a plant or bacterial toxin has been termed an “immunotoxin”. One such toxin, ricin, like most toxic proteins produced by bacteria and plants, has a toxic polypeptide (A chain) attached to a cell binding polypeptide (B chain) (Olsnes and Pihl, 1973). The B chain is a lectin that binds to galactose-containing glycoproteins or glycolipids on the cell surface. By mechanisms that are not yet well understood, the A chain of the cell-bound ricin gains access to the cell cytoplasm presumably by receptor-mediated endocytosis and penetration of the membrane of the endocytic vesicle (Olsnes and Pihl, in press). There is evidence that the B chain can also facilitate the translocation of the A chain through the membrane of the endocytic vesicle, possibly by forming a pore (Jansen, et al., 1982; Neville and Youle, 1982; Thorpe and Ross, 1982; Houston, 1982). In the cytoplasm, the A chain of ricin inhibits protein synthesis by enzymatically inactivating the EF-2 binding portion of the 60S ribosomal subunit.

Keywords

Chronic Lymphocytic Leukemia Endocytic Vesicle Daudi Cell Total Lymphoid Irradiation Prolymphocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Houston, L.L., 1982, Transport of ricin A chain after prior treatment of mouse leukemia cells with ricin B chain, J. Biol. Chem., 257:1532.PubMedGoogle Scholar
  2. Jansen, F.K., Blythman, H.E., Carriere, D., Casellas, P., Gros, O., Gros, P., Laurent, J.C., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Vidal, H. and Voison, G.A., 1982, Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity, Immunol. Rev., 62:185PubMedCrossRefGoogle Scholar
  3. Krolick, K.A., Uhr, J.W., Slavin, S. and Vitetta, E.S., 1982a, In-vivo therapy of a murine B cell tumor (BCL1) using anti-body-ricin A chain immunotoxins, J. Exp. Med., 155:1797.PubMedCrossRefGoogle Scholar
  4. Krolick, K.A., Uhr, J.W. and Vitetta, E.S., 1982b, Selective killing of leukemia cells by antibody-toxin conjugates; implications for autologous bone marrow transplantation in the treatment of cancer, Nature, 295:604.PubMedCrossRefGoogle Scholar
  5. Krolick, K.A., Villemez, C., Isakson, P., Uhr, J.W. and Vitetta, E.S., 1980, Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin, Proc. Natl. Acad. Sci. USA, 77:5419.PubMedCrossRefGoogle Scholar
  6. Muirhead, M.J., Holbert, M.H., Uhr, J.W. and Vitetta, E.S., 1981, BCL1, a murine model of prolymphocytic leukemia, Amer. J. Pathol., 105:306.Google Scholar
  7. Muirhead, M.J., Martin, P.J., Torok-Storb, B., Uhr, J.W. and Vitetta, E.S., 1983, Use of an antibody-ricin A chain conjugate to delete neoplastic B cells from human bone marrow, Blood, 62:337.Google Scholar
  8. Neville, D.M., Jr. and Youle, K.J., 1982, Monoclonal antibody ricin or ricin A chain hybrids: Kinetic analysis of cell killing for tumor therapy, Immunol. Rev., 62:75.PubMedCrossRefGoogle Scholar
  9. Olsnes, S. and Pihl, A., 1973. Different biological properties of the two constituent peptide chains of ricin. A toxic protein inhibiting protein synthesis, Biochemistry, 12:3121.PubMedCrossRefGoogle Scholar
  10. Olsnes, S. and Pihl, A., 1981, Chimeris toxins, in: “Pharmacology of Bacterial Toxins”, J. Drews and F. Domes, eds., Pergamon Press, New York.Google Scholar
  11. Slavin, S. and Strober, S., 1977, Spontaneous murine B cell leukemia, Nature, 272:624.CrossRefGoogle Scholar
  12. Thorpe, P.E., Mason, DoW., Brown, A.N.F., Simmonds, S.J., Ross, W.C.J., Cumber, A.J. and Forrester, J.A., 1982, Selective killing of malignant cells in a leukemic rat bone marrow using an antibody ricin conjugate, Nature, 297:594.PubMedCrossRefGoogle Scholar
  13. Thorpe, P.E. and Ross, W.C.J.,1982, The preparation and cytotoxic properties of antibody toxin conjugates, Immunol. Rev., 62:119.PubMedCrossRefGoogle Scholar
  14. Vitetta, E.S., Cushley, W. and Uhr, J.W., 1983, Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in-vitro killing of neoplastic human B cells, Proc. Natl. Acad. Sci. USA, 80:6332.PubMedCrossRefGoogle Scholar
  15. Vitetta, E.S., Krolick, K.A. and Uhr, J.W., 1982, Neoplastic B cells as targets for antibody-ricin A chain, Immunol. Rev., 62:159.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Ellen S. Vitetta
    • 1
  • Jonathan W. Uhr
  1. 1.Department of Microbiology, Southwestern Medical SchoolUniversity of TexasDallasUSA

Personalised recommendations